# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Cantor Fitzgerald Conference
- Reuters
Bio-Thera Solutions, Ltd. today announced, in collaboration with Biogen, the publication in the journal Arthritis Research &...
Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediate...
Cantor Fitzgerald analyst Eric Schmidt reiterates Biogen (NASDAQ:BIIB) with a Overweight and maintains $292 price target.
Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highligh...
Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor ...